재고 위치

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

1807632-95-6Dapagliflozin EP Impurity A

● 재고 있음

카탈로그 번호:	VE007776
CAS 번호:	1807632-95-6
분자식:	C21H25BrO6
분자량:	453.32 g/mol

견적 요청

RFQ 목록에 추가

에 대한 추가 정보 CAS 1807632-95-6

모약물

Dapagliflozin

IUPAC명

(1S)-1, 5-Anhydro-1-C-[4-bromo-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol

약전 동의어

Dapagliflozin Related Compound A

Other Synonyms

Dapagliflozin 4-Bromo Analog; (2S,3R,4R,5S,6R)-2-[4-Bromo-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran3,4,5-triol

SMILES

O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)C2=CC(CC3=CC=C(C=C3)OCC)=C(C=C2)Br

InChI

InChI=1S/C21H25BrO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1

설명

Dapagliflozin EP Impurity A also known as Dapagliflozin Related Compound A, in various pharmacopoeias, is a highly characterized standard. It meets strict regulatory requirements set by USP, EMA, JP, and BP, making it a crucial component in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Dapagliflozin.

References

KARUMANCHI, KISHORE, et al. â€œSynthesis of Metabolites of Dapagliflozin: An SGLT2 Inhibitor.â€ Journal of Chemical Sciences, vol. 132, no. 1, Feb. 2020, https://doi.org/10.1007/s12039-020-1747-x.?Wiviott, Stephen D., et al. â€œDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.â€ The New England Journal of Medicine, vol. 380, no. 4, 2019, pp. 347â€“57, https://doi.org/10.1056/NEJMoa1812389.?